Home / Business and Economy / Greggs Boss: Weight Loss Drugs Impacting Bakery Sales
Greggs Boss: Weight Loss Drugs Impacting Bakery Sales
8 Jan
Summary
- Greggs CEO notes appetite suppressants affect sales, driving demand for healthier options.
- The bakery introduced smaller portions and protein-rich products to cater to new trends.
- Greggs reported a 7.4% total sales jump in the last quarter despite market challenges.

Greggs' chief executive, Roisin Currie, has stated that appetite-suppressing medications are undoubtedly impacting the bakery chain's business. She noted a clear consumer shift towards smaller portions and an interest in nutritional information regarding protein and fiber content. This trend is prompting Greggs to adjust its offerings to meet these evolving customer preferences.
Currie clarified that while the rise of GLP-1 medications, known for suppressing appetite, is a factor, it aligns with a broader societal health trend. To capitalize on this, Greggs has introduced new healthier products, selling half a million egg pots since their autumn launch and recently adding an overnight oats option. Despite these shifts, hot snacks also remain popular, with 1.3 million hot food items sold weekly on average.




